Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Olmesartan, Prasugrel to Drive Sales of Daiichi Sankyo to ¥1,150 Bil. in FY2012
March 29, 2010
- GLs Drafted by JPMA for Increased Disclosure on Funds Provided to Med Inst.
March 29, 2010
- Hizentra for PI Approved by FDA: CSL Behring
March 29, 2010
- Eisai Breaks Ground for New Pilot Plant for Biologics
March 29, 2010
- NDA for Lurasidone for Schizophrenia Accepted by FDA: DSP
March 29, 2010
- Febuxostat Launched in Europe: Teijin
March 29, 2010
- NDA for Bendamustine Submitted in Taiwan: SymBio
March 29, 2010
- Quintiles Relocates Its Global Central Lab in Japan to Tokyo
March 29, 2010
- Dry AMD Treatment ACU-4429 Receives Fast-Track Designation from the FDA: Otsuka, Acucela
March 29, 2010
- NBI Posts Large Fall in Profits Despite 2.4% Increase in Sales
March 29, 2010
- Treatment of AD Shows Shift from Symptomatic Treatment to Causal Therapy
March 29, 2010
- CMIC Ties Up with Biomedical Systems for Image Analysis
March 29, 2010
- Kyowa Kirin Completes New Plant for Investigational Antibodies
March 29, 2010
- Toho to Acquire 2 More Dispensing Pharmacy Chains
March 29, 2010
- Cabazitaxel Increases OS in Advanced Hormone-Refractory Prostate Cancer
March 29, 2010
- Gifu Pref. Orders Taiyo Yakuhin's Takayama Plant to Stop Operation
March 29, 2010
- Sutent Fails to Meet Primary Endpoint in PIII for Advanced Breast Cancer
March 29, 2010
- Towa to Increase Its Number of MRs to 450
March 29, 2010
- Ghrelin Attracts Attention at Protein Mall Kansai
March 29, 2010
- PMDA to Review Applications for Priority Products within 10 Months
March 29, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…